PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

Condition(s) studied

Investigational drug(s) / intervention(s)

Prothrombin induced by vitamin K absence II (PIVKA-II): Serum PIVKA-II level will be measured in HCC patients with and without PVTT.

Study summary

The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients.

Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT.

Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).

Eligibility

Primary outcome measure(s)

• PIVKA-II serum level for prediction of PVTT in HCC patients. — through study completion, an average of 1 year
  PIVKA-II level (mAU/mL) will be measured in serum of HCC patients with and without PVTT.

Trial sites (1)

More Tanta University trials in Egypt

Other trials for the same condition